% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zhang:15880,
      author       = {Zhang, B. and Yu, W. and Zhao, Q.T. and Buca, D. and
                      Holländer, B. and Hartmann, J.M. and Zhang, M. and Wang, X.
                      and Mantl, S.},
      title        = {{I}mproved {N}i{S}i0.8{G}e0.2/{S}i0.8{G}e0.2 {C}ontacs by
                      {C}+ {P}re-{I}mplantation},
      journal      = {Electrochemical and solid-state letters},
      volume       = {14},
      issn         = {1099-0062},
      address      = {Pennington, NJ},
      publisher    = {Soc.},
      reportid     = {PreJuSER-15880},
      pages        = {H261-H263},
      year         = {2011},
      note         = {This work was supported by the German Federal Ministry of
                      Education and Research via the MEDEA+ project
                      DECI-SIF(2T104). Additional funding was received by the
                      Nanosil network from the European Community (FP7 grant No.
                      216171). B. Zhang thanks the National Natural Science
                      Foundation of China under Grant No. 61006088 and, together
                      with W. Yu to the China Scholarship Council for the
                      financial support.},
      abstract     = {This open-label extension evaluated the long-term efficacy
                      and tolerability of rufinamide in patients with
                      Lennox-Gastaut syndrome (LGS) who had previously completed a
                      12-week double-blind study.In total, 124 patients (aged 4-37
                      years), receiving 1-3 concomitant antiepileptic drugs, were
                      treated with rufinamide approximately 25-60 mg/kg/day.
                      Efficacy was assessed by seizure frequency; tolerability by
                      adverse events (AEs) and laboratory tests.Overall, patients
                      were treated with rufinamide for a median (range) of 432
                      (10-1149) days. Reductions in seizure frequency were
                      observed throughout the study; during the last 12 months of
                      treatment, $41.0\%$ and $47.9\%$ of patients had > or =
                      $50\%$ reduction in total and tonic-atonic seizure
                      frequency, respectively. The most common AEs were vomiting
                      $(30.6\%)$ and pyrexia $(25.8\%).In$ this open-label
                      extension, rufinamide appeared to be an effective long-term
                      adjunctive therapy for the treatment of LGS-associated
                      seizures in children and young adults.},
      keywords     = {J (WoSType)},
      cin          = {JARA-FIT / PGI-9},
      ddc          = {540},
      cid          = {$I:(DE-82)080009_20140620$ / I:(DE-Juel1)PGI-9-20110106},
      pnm          = {Grundlagen für zukünftige Informationstechnologien /
                      NANOSIL - Silicon-based nanostructures and nanodevices for
                      long term nanoelectronics applications (216171)},
      pid          = {G:(DE-Juel1)FUEK412 / G:(EU-Grant)216171},
      shelfmark    = {Electrochemistry / Materials Science, Multidisciplinary},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000290276400011},
      doi          = {10.1149/1.3578387},
      url          = {https://juser.fz-juelich.de/record/15880},
}